Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520468 · ClinicalTrials.gov registry record · Phase 2
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00520468: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00520468 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00520468, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk myelodysplastic syndromes (MDS). Secondary: To evaluate response duration, survival and side effects of the treatment.
Interventions
- DRUG G-CSF
- DRUG Prednisone
- DRUG Erythropoietin
- DRUG Cyclosporin A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520468
The ClinicalTrials.gov registry entry for NCT00520468 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which G-CSF is the first listed.
NCT00520468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00520468 about?
NCT00520468 is a clinical study titled "Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS". Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk myelodysplastic syndromes (MDS). Secondary: To evaluate response duration, survival and side effects of the treatment.
What is the current status of trial NCT00520468?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2004-06. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00520468?
The interventions under investigation include: G-CSF (DRUG), Prednisone (DRUG), Erythropoietin (DRUG), Cyclosporin A (DRUG).
Who is sponsoring clinical trial NCT00520468?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.